AUTHOR=Zeng Daobing , Zhao Xiaofei , Di Liang , Lou Luyan , Song Yanfang , Zhang Yanrui , Liu Huanhuan , Li Guangming 

TITLE=Effectiveness of Trastuzumab Combined With Capecitabine Treatment in a Patient With Hilar Cholangiocarcinoma Complicated by Liver Metastases With an ERBB2-Activating Mutation: A Case Report

JOURNAL=Frontiers in Oncology

VOLUME=12

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.918297

DOI=10.3389/fonc.2022.918297

ISSN=2234-943X

ABSTRACT=<p>The identification of <italic>ERBB2</italic> (<italic>HER2</italic>) alteration in some solid tumors has become critically important due to the actionable events predictive of response to anti-HER2 therapy. However, the efficacy of <italic>ERBB2</italic> mutated hilar cholangiocarcinoma (hCCA) against ERBB2 is rarely reported. Here we report a 76-year-old female diagnosed with hCCA complicated by liver metastases after radical resection. The next-generation sequencing assay showed that the tumor had an <italic>ERBB2</italic> mutation. Then, the patient was treated with trastuzumab plus capecitabine. After 2 months of treatment, she had a partial response. Until now, the patient is still alive. This study has shown the potential of trastuzumab combined with capecitabine as an effective treatment for hilar cholangiocarcinoma complicated by liver metastases harboring <italic>ERBB2</italic> alterations.</p>